Clinical trials: Attention Disorder
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
This study will evaluate the efficacy and safety of high doses of SPN 812 in children with ADHD
- Trial name
- NCT03247543
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 10 sites in United States
- Volunteers
- 313 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Huntington Disease, Alzheimer Disease
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose…
- Trial name
- NCT00788047
- Testing
- Dextromethorphan, Dimebon + Dextromethorphan
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Attention-deficit/Hyperactivity Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01552902
- Testing
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride
- Where
- 95 sites in United States, Canada and 3 more
- Volunteers
- 549 people
- Sponsor
- Shire
Wilson Disease
Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
The main objective of the study is to evaluate the change in liver copper (Cu) concentration following 48 weeks of treatment with ALXN1840 in adult participants with Wilson Disease (WD) who have been previously treated for at…
- Trial name
- NCT04422431
- Testing
- Bis-Choline Tetrathiomolybdate
- Where
- 12 sites in United States, Canada and 6 more
- Volunteers
- 31 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Huntington's Disease
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease.
- Trial name
- NCT02197130
- Testing
- PF-02545920
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 272 people
- Sponsor
- Pfizer
Healthy, Alzheimer's Disease
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's…
- Conditions
- Healthy, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- NCT02614131
- Testing
- LY2599666, Solanezumab
- Where
- 5 sites in United States, Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Parkinson's Disease
To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers
To evaluate the pharmacokinetics of AZD3241 following multiple administration of 2 new, different extended release formulations of tablets of AZD3241 (300 mg), in relation to the 100 mg extended release tablet used in a previous…
- Trial name
- NCT01457807
- Testing
- AZD3241 ER formulation 1, AZD3241 Alternative titration scheme with formulation 1 or 2
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cognitive Impairment Associated With Schizophrenia (CIAS)
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days.
- Trial name
- NCT07191483
- Testing
- KYN-5356 low dose, KYN-5356 Medium Dose, KYN-5356 High Dose
- Where
- 15 sites in United States
- Volunteers
- 149 people
- Sponsor
- Kynexis B.V.
Alzheimer's Disease, Mild Cognitive Impairment
Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose study of ABT-957 in participants with mild Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) due to AD.
- Trial name
- NCT02573740
- Testing
- ABT-957
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- AbbVie
Attention-Deficit Hyperactivity Disorder (ADHD)
PDC-1421 Treatment in Adult Patients With ADHD
Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.
- Trial name
- NCT05202327
- Testing
- PDC-1421 Capsule
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 99 people
- Sponsor
- BioLite, Inc.
Attention Deficit/Hyperactivity Disorder
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
This is a multicenter, dose-optimized, randomized, double-blind, placebo controlled, efficacy and safety study with Azstarys® in children 4 to 12 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P01 (NCT05685732)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 246 people
- Sponsor
- Corium, Inc.
Attention-Deficit/Hyperactivity Disorder
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over…
- Trial name
- RE-DAX (NCT04507204)
- Testing
- Adhansia XR, Concerta
- Where
- 35 sites in United States
- Volunteers
- 267 people
- Sponsor
- Purdue Pharma LP
Chronic Shift Work Sleep Disorder
Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL
The purpose of the study is to compare the overnight efficacy and plasma concentration-time profiles of armodafinil and PROVIGIL, after multiple doses, in patients with excessive sleepiness associated with chronic Shift Work…
- Trial name
- NCT00236080
- Testing
- PROVIGIL 200 mg, Armodafinil 250 mg, Armodafinil 200 mg
- Where
- 20 sites in United States
- Volunteers
- 136 people
- Sponsor
- Cephalon
Post-Operative Confusion
Braindex Cerebral Tissue Oxygen Saturation (SctO2) Measurement Algorithm Assessment and Improvement
The objective of this clinical trial is to optimize Braindex brain tissue oxygen saturation (SctO2) measurement algorithm compared to a mixed reference value of jugular venous and systemic arterial saturation, during proven…
- Trial name
- POC-SctO2 (NCT05897060)
- Testing
- Venus Jugular O2 Saturation optical fiber
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Braindex
Cognitive Disorders
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy male subjects following single or multiple ascending doses.
- Trial name
- NCT02342041
- Testing
- SUVN-G3031
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic response of repeated intravenous infusions of BAN2401 in subjects with mild cognitive impairment (MCI) due to…
- Trial name
- NCT02094729
- Testing
- BAN2401 2.5 mg/kg, BAN2401 5 mg/kg, BAN2401 10 mg/kg
- Where
- 4 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Eisai Co., Ltd.
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder
GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs
The purpose of this study is to examine the use of, and reaction to, one particular software application(GroundsKeeper) delivered on unique platform - Sifteo cubes (www.sifteo.com).
- Conditions
- Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Pervasive Developmental Disorder, Asperger's Disorder
- Trial name
- NCT01808066
- Testing
- Groundskeeper
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- CogCubed, Corp
Mild Cognitive Impairment
Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment
The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
- Trial name
- NCT02211560
- Testing
- Phosphatidylserine
- Where
- 15 sites in United States, Israel
- Volunteers
- 97 people
- Sponsor
- Enzymotec
Memory Deficits, Cognitive Change
An Exploratory Investigation of a Supplement to Promote Brain Health
Providing a combination of synergistic dietary supplements, such as vitamins B6, B12, and folate, as well as curcumin, lemon balm, and American ginseng is hypothesized to promote brain health and aid with brain fog, mental…
- Conditions
- Memory Deficits, Cognitive Change, Stress
- Trial name
- NCT05520424
- Testing
- The Daily Supplement
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Parable
Parkinson's Disease
A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients
In this Phase I/IIa study, the effect of continuous subcutaneous administration of LD/CD solution (ND0612) on the safety and PK profile of LD will be examined.
- Trial name
- NCT01725802
- Testing
- Levodopa/carbidopa solution for SC administration
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- NeuroDerm Ltd.